[HTML][HTML] Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non–Small-Cell …
M Reck, EB Garon, L Paz-Ares, S Ponce, JC Jaime… - Clinical lung cancer, 2018 - Elsevier
… of medical research judged not to be scientifically or medically compatible with this study.
Patients participating in surveys or observational studies are eligible to participate in this study. …
Patients participating in surveys or observational studies are eligible to participate in this study. …
Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTTION observational study
A Vergnenegre, EF Smit, E Toy, B Parente… - … medical research and …, 2012 - Taylor & Francis
… erlotinib cohort comprised substantially different patients compared with the pemetrexed and
docetaxel cohorts: patients in the erlotinib … all cohorts, erlotinib patients tended to continue …
docetaxel cohorts: patients in the erlotinib … all cohorts, erlotinib patients tended to continue …
Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010–2016 in Sweden: a nationwide observational study
M Bergqvist, HN Christensen, F Wiklund… - … Journal of Cancer, 2020 - Wiley Online Library
… Utilizing Swedish nationwide registers, we identified all Stage IIIB–IV NSCLC patients …
, during the observation period, survival improved for EGFR TKI treated NSCLC patients, as …
, during the observation period, survival improved for EGFR TKI treated NSCLC patients, as …
… inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case–control study of overall survival
M Faehling, R Eckert, T Kamp, S Kuom, U Griese… - Lung cancer, 2013 - Elsevier
… Two recent observational studies in Asian patients reported prolonged benefit of continued
erlotinib treatment in patients who developed bone or cerebral metastases on EGFR-TKI …
erlotinib treatment in patients who developed bone or cerebral metastases on EGFR-TKI …
FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets
MH Cohen, JR Johnson, YF Chen, R Sridhara… - The …, 2005 - academic.oup.com
… patients was randomized using a 2:1 randomization schema—488 patients in the erlotinib
arm and 243 patients in … EGFR status was determined for 238 of the 731 study patients (33%) …
arm and 243 patients in … EGFR status was determined for 238 of the 731 study patients (33%) …
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
F Cappuzzo, T Ciuleanu, L Stelmakh, S Cicenas… - The lancet …, 2010 - thelancet.com
… [9%] of 443 patients in the erlotinib group vs none of 445 in … patients vs none of 445). Serious
adverse events were reported in 47 patients (11%) on erlotinib compared with 34 patients (8…
adverse events were reported in 47 patients (11%) on erlotinib compared with 34 patients (8…
Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors
J Rosentreter, J Alt, M Fried… - Journal of oncology …, 2021 - journals.sagepub.com
… It is noteworthy that in the present study not a single patient was treated with erlotinib, …
studies on medication adherence in NSCLC patients were almost exclusively on erlotinib, …
studies on medication adherence in NSCLC patients were almost exclusively on erlotinib, …
Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study …
V Sarosi, G Losonczy, E Francovszky, E Tolnay… - Lung Cancer, 2014 - Elsevier
… Our results suggest that erlotinib represents a valid treatment option for patients with KRAS
WT … clinically relevant subgroups of NSCLC patients that may benefit from EGFR-TKI therapy. …
WT … clinically relevant subgroups of NSCLC patients that may benefit from EGFR-TKI therapy. …
Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non–small cell lung cancer: a phase 2 …
TE Stinchcombe, PA Jänne, X Wang, EM Bertino… - JAMA …, 2019 - jamanetwork.com
… the erlotinib arm in our study … study found a longer PFS in the patients with a T790M mutation
detected in pretreatment specimen. This observation has not been validated in other studies…
detected in pretreatment specimen. This observation has not been validated in other studies…
[HTML][HTML] The combination of afatinib and bevacizumab in untreated EGFR-mutated advanced lung adenocarcinoma: a multicenter observational study
PC Hsu, CY Huang, CC Wang, SCH Kuo, CH Chu… - Pharmaceuticals, 2020 - mdpi.com
… occurred in 12 patients (21.1%) in this study, whereas this … In this study, the occurrence
rate of T790M mutation in patients … The BELIEF study reported that erlotinib combined with …
rate of T790M mutation in patients … The BELIEF study reported that erlotinib combined with …